Blood and urine samples collection

DIAGNOSTIC_TEST3 trials

Sponsors

Novartis Pharma Services inc., Full-Life Technologies GmbH, Unidade Local de Saúde de Coimbra, EPE

Conditions

Diabetes MellitusDiabetes Mellitus, Type 1Heterozygous Familial Hypercholesterolemia heterozygous familial hypercholesterolemiaMetastatic Castration-resistant Prostate Cancer

Phase 1

Study With [225Ac]Ac-FL-020 in mCRPC Participants

RecruitingNCT06492122

Full-Life Technologies GmbHMetastatic Castration-resistant Prostate Cancer

Start: 2024-08-30End: 2026-12-01Target: 50Updated: 2026-01-29

Phase 3

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia

Active, not recruitingLBCTR2021034776

Novartis Pharma Services inc.Heterozygous Familial Hypercholesterolemia heterozygous familial hypercholesterolemia

Start: 2021-08-31Target: 4Updated: 2026-02-02

Unknown Phase

Urine Extracellular Vesicles: Non-invasive Biomarkers of Β-cell Function and Novel Therapeutic Agents in Diabetes

Active, not recruitingNCT06832215

Unidade Local de Saúde de Coimbra, EPEDiabetes Mellitus, Diabetes Mellitus, Type 1

Start: 2023-05-06End: 2027-03-30Updated: 2025-02-18

Related Papers

A first-in-human, phase 1 dose escalation and expansion study evaluating the safety, tolerability, and anti-tumor activity of [225Ac]Ac-FL-020, an anti-PSMA radioconjugate, in patients with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2025-05-28